High-dose melphalan with or without stem cell support before myeloablative allo-SCT for remission induction in patients with advanced relapsed or refractory AML

被引：0
作者：
A O'Meara
T Pabst
D Heim
S Gerull
C Bucher
J Halter
C Arber
A Rovò
A Tichelli
A Gratwohl
M Stern
机构：
[1] University Hospital of Basel,Division of Hematology, Department of Internal Medicine
[2] Institute of Medical Oncology,Department of Internal Medicine
来源：
Bone Marrow Transplantation | 2011年 / 46卷
关键词：
AML; melphalan; auto-SCT; allo-SCT;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Treatment strategies for relapsed/refractory AML are limited and disappointing. Recently, high-dose melphalan (HDM) chemotherapy and autologous hematopoietic SCT (HSCT) has been proposed for AML re-induction. We investigated the impact of HDM remission induction in highly advanced relapsed/refractory AML patients planned for allogeneic HSCT. A total of 23 patients with relapsed/refractory AML were prospectively scheduled for HDM with or without stem cell support followed by myeloablative allogeneic HSCT. Patients included nine individuals with a history of previous HSCT (seven allogeneic, two autologous). A total of 18 patients (78%) achieved a leukemia-free state and an additional four had substantial reduction of the initial leukemia burden warranting treatment continuation. There were no differences between patients with or without immediate stem cell support regarding mucositis or other organ toxicity. A total of 20 patients proceeded to myeloablative allogeneic HSCT. Outcome of allogeneic HSCT was poor: 11 patients (55%) relapsed, 7 patients (35%) died from TRM and only 2 patients (10%) were alive at the last follow-up. Our study shows that HDM is effective in inducing a leukemia-free state in patients with highly advanced relapsed/refractory AML. Leukemia burden reduction with HDM, however, did not translate into improved OS.
引用
收藏
页码：636 / 640
页数：4
相关论文
共 66 条
  • [1] Estey E(2006)Acute myeloid leukaemia Lancet 368 1894-1907
  • [2] Dohner H(1988)The systemic administration of intravenous melphalan J Clin Oncol 6 1768-1782
  • [3] Sarosy G(2010)BU/melphalan and auto-SCT in AML patients in first CR: a ‘Gruppo Italiano Trapianto di Midollo Osseo (GITMO)’ retrospective study Bone Marrow Transplant 45 640-646
  • [4] Leyland-Jones B(1985)Repeated high-dose-melphalan with autologous bone marrow transplantation in acute non lymphocytic leukemia Rev Fr Transfus Immunohematol 28 477-488
  • [5] Soochan P(1993)Results of intensive therapy in childhood acute myeloid leukemia, incorporating high-dose melphalan and autologous bone marrow transplantation in first complete remission Blood 82 3730-3738
  • [6] Cheson BD(1986)High-dose melphalan with or without marrow transplantation: a study of dose-effect in patients with refractory and/or relapsed acute leukemias Cancer Treat Rep 70 445-448
  • [7] Lemoli RM(2000)High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant Bone Marrow Transplant 26 333-338
  • [8] D’Addio A(2005)High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation Ann Hematol 84 748-754
  • [9] Marotta G(2010)Double allogeneic hematopoietic SCT as a rescue therapy for poor-risk hematological malignancies Bone Marrow Transplant 45 103-109
  • [10] Pezzullo L(2003)Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia J Clin Oncol 21 4642-4649
1234567